Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC to Present at Upcoming Investor Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Present at the 4th Annual Gene Therapy for Rare Disorders Digital Event, February 22-25, 2021
-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development ---- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
View HTML
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2020
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 - - Net proceeds of approximately $69.2 million from a recent public offering provide cash runway into calendar year 2023 - - Company to host conference call and webcast today at 8:00 a.m.
View HTML
Toggle Summary AGTC Executives Awarded First Place in the BioProcess International Reader’s Choice Awards, Cell & Gene Therapies Category
Article reflects Company’s leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company
View HTML
Toggle Summary AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Pricing of Public Offering of Common Stock and Warrants
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
View HTML
Toggle Summary AGTC Announces Proposed Public Offering of Common Stock and Warrants
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Announces First Reported Improvements in Visual Sensitivity for Achromatopsia (ACHM) patients from its Ongoing Clinical Trials
-Preliminary results suggest sustained improvements to 12-months in visual sensitivity, as measured by full field static perimetry, supported in some patients by other endpoints- -Company plans longer term follow-up, dosing of younger pediatric patients, and addition of new brain imaging and color
View HTML
Toggle Summary AGTC to Participate in the H.C. Wainwright BioConnect 2021 Conference
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that Sue
View HTML
Visionary science for life changing cures.